RU2018143895A - FORMATED BY MEDIUM-RADIATED FATTY ACIDS, COMPLEXES OF BETA HYDROXIBUTIRATE AND BUTANDIOL, AND COMPOSITIONS AND METHODS ON THEIR BASIS - Google Patents

FORMATED BY MEDIUM-RADIATED FATTY ACIDS, COMPLEXES OF BETA HYDROXIBUTIRATE AND BUTANDIOL, AND COMPOSITIONS AND METHODS ON THEIR BASIS Download PDF

Info

Publication number
RU2018143895A
RU2018143895A RU2018143895A RU2018143895A RU2018143895A RU 2018143895 A RU2018143895 A RU 2018143895A RU 2018143895 A RU2018143895 A RU 2018143895A RU 2018143895 A RU2018143895 A RU 2018143895A RU 2018143895 A RU2018143895 A RU 2018143895A
Authority
RU
Russia
Prior art keywords
alkyl
compound
unsubstituted
compound according
paragraphs
Prior art date
Application number
RU2018143895A
Other languages
Russian (ru)
Other versions
RU2018143895A3 (en
RU2761829C2 (en
Inventor
Эрик ВЕРДИН
Скотт УЛЬРИХ
Джон НЬЮМАН
Original Assignee
Зе Дж. Дэвид Глэдстоун Инститьютс
Зе Реджентс Оф Зе Юниверсити Оф Калифорния
Итака Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Дж. Дэвид Глэдстоун Инститьютс, Зе Реджентс Оф Зе Юниверсити Оф Калифорния, Итака Колледж filed Critical Зе Дж. Дэвид Глэдстоун Инститьютс
Publication of RU2018143895A publication Critical patent/RU2018143895A/en
Publication of RU2018143895A3 publication Critical patent/RU2018143895A3/ru
Application granted granted Critical
Publication of RU2761829C2 publication Critical patent/RU2761829C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/045—Organic compounds containing nitrogen as heteroatom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)

Claims (80)

1. Соединение формулы I:1. The compound of formula I:
Figure 00000001
Figure 00000001
 гдеWhere R1 представляет собой Н, или С(1-6) алкил, или замещенный алкил; иR 1 represents H, or C (1-6) alkyl, or substituted alkyl; and R2 и R3 независимо представляют собой незамещенный или замещенный С(4-30) алкил.R 2 and R 3 independently represent unsubstituted or substituted C (4-30) alkyl. 2. Соединение по п. 1, где R1 представляет собой незамещенный С(1-6) алкил.2. The compound of claim 1, wherein R 1 is unsubstituted C (1-6) alkyl. 3. Соединение по п. 2, где R1 представляет собой метил.3. The compound of claim 2, wherein R 1 is methyl. 4. Соединение по любому из пп. 1-3, где R2 и R3 независимо представляют собой незамещенный С(6-18) алкил.4. The compound according to any one of paragraphs. 1-3, where R 2 and R 3 independently represent unsubstituted C (6-18) alkyl. 5. Соединение по любому из пп. 1-3, где R2 и R3 независимо представляют собой незамещенный С6 алкил или незамещенный С8 алкил.5. The compound according to any one of paragraphs. 1-3, where R 2 and R 3 independently represent unsubstituted C6 alkyl or unsubstituted C8 alkyl. 6. Соединение по п. 1, имеющее формулу Ia:6. The compound according to claim 1, having the formula Ia:
Figure 00000002
Figure 00000002
 гдеWhere R1 представляет собой Н, или С(1-6) алкил, или замещенный алкил; иR 1 represents H, or C (1-6) alkyl, or substituted alkyl; and R2 и R3 независимо представляют собой незамещенный или замещенный С(4-30) алкил.R 2 and R 3 independently represent unsubstituted or substituted C (4-30) alkyl. 7. Соединение по п. 6, где R1 представляет собой незамещенный С(1-6) алкил.7. The compound of claim 6, wherein R 1 is unsubstituted C (1-6) alkyl. 8. Соединение по п. 6, где R1 представляет собой метил.8. The compound of claim 6, wherein R 1 is methyl. 9. Соединение по любому из пп. 6-8, где R2 и R3 независимо представляют собой незамещенный С(6-18) алкил.9. The compound according to any one of paragraphs. 6-8, where R 2 and R 3 independently represent unsubstituted C (6-18) alkyl. 10. Соединение по п. 9, где R2 и R3 независимо представляют собой незамещенный С6 алкил или незамещенный С8 алкил.10. The compound of claim 9, wherein R 2 and R 3 independently are unsubstituted C6 alkyl or unsubstituted C8 alkyl. 11. Соединение по п. 1, имеющее формулу Ib:11. The compound according to claim 1, having the formula Ib:
Figure 00000003
Figure 00000003
 гдеWhere R1 представляет собой Н, или С(1-6) алкил, или замещенный алкил; иR 1 represents H, or C (1-6) alkyl, or substituted alkyl; and R2 и R3 независимо представляют собой незамещенный или замещенный С(4-30) алкил.R 2 and R 3 independently represent unsubstituted or substituted C (4-30) alkyl. 12. Соединение по п. 11, где R1 представляет собой незамещенный С(1-6) алкил.12. The compound of claim 11, wherein R 1 is unsubstituted C (1-6) alkyl. 13. Соединение по п. 12, где R1 представляет собой метил.13. The compound of claim 12, wherein R 1 is methyl. 14. Соединение по любому из пп. 11-13, где R2 и R3 независимо представляют собой незамещенный С(6-18) алкил.14. The compound according to any one of paragraphs. 11-13, where R 2 and R 3 independently represent unsubstituted C (6-18) alkyl. 15. Соединение по п. 14, где R2 и R3 независимо представляют собой незамещенный С8 алкил.15. The compound of claim 14, wherein R 2 and R 3 independently are unsubstituted C8 alkyl. 16. Композиция, содержащая соединение по любому из пп. 1-15 и фармацевтически приемлемый носитель.16. A composition comprising a compound according to any one of paragraphs. 1-15 and a pharmaceutically acceptable carrier. 17. Способ, включающий введение нуждающемуся в этом субъекту терапевтически эффективного количества соединения по любому из пп. 1-16 или композиции по п. 17.17. A method comprising administering to a subject in need of a therapeutically effective amount of a compound according to any one of claims. 1-16 or a composition according to claim 17. 18. Способ по п. 17, где указанное терапевтически эффективное количество является достаточным для уменьшения эпилептиформной активности в головном мозге субъекта.18. The method of claim 17, wherein said therapeutically effective amount is sufficient to reduce epileptiform activity in the brain of a subject. 19. Способ лечения одного или более из болезни Альцгеймера, эпилепсии, болезни Паркинсона, сердечной недостаточности, травматического повреждения головного мозга, инсульта, геморрагического шока, острого повреждения легкого после жидкостной реанимации, острого повреждения почек, инфаркта миокарда, ишемии миокарда, диабета, мультиформной глиобластомы, диабетической нейропатии, рака предстательной железы, бокового амиотрофического склероза, болезни Хантингтона, кожной Т-клеточной лимфомы, множественной миеломы, периферической Т-кпеточной лимфомы, ВИЧ, болезни Ниманна-Пика типа С, возрастной макулярной дегенерации, подагры, атеросклероза, ревматоидного артрита и рассеянного склероза, включающий:19. A method of treating one or more of Alzheimer's disease, epilepsy, Parkinson's disease, heart failure, traumatic brain damage, stroke, hemorrhagic shock, acute lung damage after fluid resuscitation, acute kidney damage, myocardial infarction, myocardial ischemia, diabetes, glioblastoma multiforme , diabetic neuropathy, prostate cancer, amyotrophic lateral sclerosis, Huntington’s disease, cutaneous T-cell lymphoma, multiple myeloma, peripheral T-cell lymphoma, HIV, Neemann-Peak type C disease, age-related macular degeneration, gout, atherosclerosis, rheumatoid arthritis and multiple sclerosis, including: введение субъекту терапевтически эффективного количества соединения по любому из пп. 1-16 или композиции по п. 17.administering to the subject a therapeutically effective amount of a compound according to any one of claims. 1-16 or a composition according to claim 17. 20. Способ по п. 19, где указанное терапевтически эффективное количество является достаточным для уменьшения эпилептиформной активности в головном мозге субъекта.20. The method of claim 19, wherein said therapeutically effective amount is sufficient to reduce epileptiform activity in the brain of a subject. 21. Способ уменьшения эпилептиформной активности в головном мозге субъекта, включающий введение указанному субъекту терапевтически эффективного количества соединения по любому из пп. 1-16 или композиции по п. 17.21. A method of reducing epileptiform activity in the brain of a subject, comprising administering to said subject a therapeutically effective amount of a compound according to any one of claims. 1-16 or a composition according to claim 17. 22. Пищевая добавка, содержащая соединение по любому из пп. 1-16.22. A food supplement containing a compound according to any one of paragraphs. 1-16. 23. Композиция, содержащая:23. A composition comprising: пищевую добавку, содержащую соединение по любому из пп. 1-16; иa nutritional supplement containing a compound according to any one of paragraphs. 1-16; and один или более дополнительных компонентов кетогенной диеты.one or more additional components of a ketogenic diet. 24. Композиция по п. 23, отличающаяся тем, что содержание указанного соединения в композиции составляет от примерно 1% масс./масс. до примерно 25% масс./масс., или от примерно 5% масс./масс. до примерно 15% масс./масс., или примерно 10% масс./масс.24. The composition of claim 23, wherein the content of said compound in the composition is from about 1% w / w. up to about 25% wt./mass., or from about 5% wt./mass. up to about 15% wt./mass., or about 10% wt./mass. 25. Композиция по п. 23, где указанная кетогенная диета включает массовое отношение жира к белку и углеводам, составляющее от примерно 2:1 до примерно 10:1, или массовое отношение жира к белку и углеводам, составляющее от примерно 3:1 до примерно 6:1, или кетогенная диета включает массовое отношение жира к белку и углеводам, составляющее примерно 4:1.25. The composition according to p. 23, where the specified ketogenic diet includes a mass ratio of fat to protein and carbohydrates, comprising from about 2: 1 to about 10: 1, or a mass ratio of fat to protein and carbohydrates, from about 3: 1 to about 6: 1, or a ketogenic diet includes a mass ratio of fat to protein and carbohydrates of about 4: 1. 26. Соединение формулы II:26. The compound of formula II:
Figure 00000004
Figure 00000004
 гдеWhere R4 представляет собой Н, или С(1-6) алкил, или замещенный алкил; иR 4 represents H, or C (1-6) alkyl, or substituted alkyl; and R5 и R6 независимо представляют собой незамещенный или замещенный С(4-30) алкил.R 5 and R 6 independently represent unsubstituted or substituted C (4-30) alkyl. 27. Соединение по п. 26, где R4 представляет собой незамещенный С(1-6) алкил.27. The compound of claim 26, wherein R 4 is unsubstituted C (1-6) alkyl. 28. Соединение по п. 27, где R4 представляет собой метил.28. The compound of claim 27, wherein R 4 is methyl. 29. Соединение по любому из пп. 26-28, где R5 и R6 независимо представляют собой незамещенный С(6-18) алкил.29. The compound according to any one of paragraphs. 26-28, where R 5 and R 6 independently represent unsubstituted C (6-18) alkyl. 30. Соединение по п. 29, где R5 и R6 независимо представляют собой незамещенный С6 алкил или незамещенный С8 алкил.30. The compound of claim 29, wherein R 5 and R 6 independently are unsubstituted C6 alkyl or unsubstituted C8 alkyl. 31. Соединение по п. 26, где указанное соединение имеет формулу IIa:31. The compound of claim 26, wherein said compound has the formula IIa:
Figure 00000005
Figure 00000005
 гдеWhere R4 представляет собой Н, или С(1-6) алкил, или замещенный алкил; иR 4 represents H, or C (1-6) alkyl, or substituted alkyl; and R5 и R6 независимо представляют собой незамещенный или замещенный С(4-30) алкил.R 5 and R 6 independently represent unsubstituted or substituted C (4-30) alkyl. 32. Соединение по п. 31, где R4 представляет собой незамещенный С(1-6) алкил.32. The compound of claim 31, wherein R 4 is unsubstituted C (1-6) alkyl. 33. Соединение по п. 32, где R4 представляет собой метил.33. The compound of claim 32, wherein R 4 is methyl. 34. Соединение по любому из пп. 31-33, где R5 и R6 независимо представляют собой незамещенный С(6-18) алкил.34. The compound according to any one of paragraphs. 31-33, where R 5 and R 6 independently represent unsubstituted C (6-18) alkyl. 35. Соединение по п. 34, где R5 и R6 независимо представляют собой незамещенный С6 алкил или незамещенный С8 алкил.35. The compound of claim 34, wherein R 5 and R 6 independently are unsubstituted C6 alkyl or unsubstituted C8 alkyl. 36. Соединение по п. 26, где указанное соединение имеет формулу IIb:36. The compound of claim 26, wherein said compound has the formula IIb:
Figure 00000006
Figure 00000006
 гдеWhere R4 представляет собой Н, или С(1-6) алкил, или замещенный алкил; иR 4 represents H, or C (1-6) alkyl, or substituted alkyl; and R5 и R6 независимо представляют собой незамещенный или замещенный С(4-30) алкил.R 5 and R 6 independently represent unsubstituted or substituted C (4-30) alkyl. 37. Соединение по п. 36, где R4 представляет собой незамещенный С(1-6) алкил.37. The compound of claim 36, wherein R 4 is unsubstituted C (1-6) alkyl. 38. Соединение по п. 37, где R4 представляет собой метил.38. The compound of claim 37, wherein R 4 is methyl. 39. Соединение по любому из пп. 36-38, где R5 и R6 независимо представляют собой незамещенный С(6-18) алкил.39. The compound according to any one of paragraphs. 36-38, where R 5 and R 6 independently represent unsubstituted C (6-18) alkyl. 40. Соединение по п. 39, где R5 и R6 независимо представляют собой незамещенный С6 алкил или незамещенный С8 алкил.40. The compound of claim 39, wherein R 5 and R 6 independently are unsubstituted C6 alkyl or unsubstituted C8 alkyl. 41. Композиция, содержащая соединение по любому из пп. 26-40 и фармацевтически приемлемый носитель.41. A composition containing a compound according to any one of paragraphs. 26-40 and a pharmaceutically acceptable carrier. 42. Способ, включающий введение нуждающемуся в этом субъекту терапевтически эффективного количества соединения по любому из пп. 26-40 или композиции по п. 41.42. A method comprising administering to a subject in need of a therapeutically effective amount of a compound according to any one of claims. 26-40 or composition according to p. 41. 43. Способ по п. 42, где указанное терапевтически эффективное количество является достаточным для уменьшения эпилептиформной активности в головном мозге субъекта.43. The method of claim 42, wherein said therapeutically effective amount is sufficient to reduce epileptiform activity in the brain of a subject. 44. Способ лечения одного или более из болезни Альцгеймера, эпилепсии, болезни Паркинсона, сердечной недостаточности, травматического повреждения головного мозга, инсульта, геморрагического шока, острого повреждения легкого после жидкостной реанимации, острого повреждения почек, инфаркта миокарда, ишемии миокарда, диабета, мультиформной глиобластомы, диабетической нейропатии, рака предстательной железы, бокового амиотрофического склероза, болезни Хантингтона, кожной Т-клеточной лимфомы, множественной миеломы, периферической Т-клеточной лимфомы, ВИЧ, болезни Ниманна-Пика типа С, возрастной макулярной дегенерации, подагры, атеросклероза, ревматоидного артрита и рассеянного склероза, включающий:44. A method of treating one or more of Alzheimer's disease, epilepsy, Parkinson's disease, heart failure, traumatic brain damage, stroke, hemorrhagic shock, acute lung damage after fluid resuscitation, acute kidney damage, myocardial infarction, myocardial ischemia, diabetes, glioblastoma multiforme , diabetic neuropathy, prostate cancer, amyotrophic lateral sclerosis, Huntington’s disease, cutaneous T-cell lymphoma, multiple myeloma, peripheral T-cell lymphoma, HIV, Nyman-Peak type C disease, age-related macular degeneration, gout, atherosclerosis, rheumatoid arthritis and multiple sclerosis, including: введение субъекту терапевтически эффективного количества соединения по любому из пп. 26-40 или композиции по п. 41.administering to the subject a therapeutically effective amount of a compound according to any one of claims. 26-40 or composition according to p. 41. 45. Способ по п. 44, где указанное терапевтически эффективное количество является достаточным для уменьшения эпилептиформной активности в головном мозге субъекта.45. The method of claim 44, wherein said therapeutically effective amount is sufficient to reduce epileptiform activity in the brain of a subject. 46. Способ уменьшения эпилептиформной активности в головном мозге субъекта, включающий введение указанному субъекту терапевтически эффективного количества соединения по любому из пп. 26-40 или композиции по п. 41.46. A method of reducing epileptiform activity in the brain of a subject, comprising administering to said subject a therapeutically effective amount of a compound according to any one of claims. 26-40 or composition according to p. 41. 47. Пищевая добавка, содержащая соединение по любому из пп. 26-40.47. A food supplement containing a compound according to any one of paragraphs. 26-40. 48. Композиция, содержащая:48. A composition comprising: пищевую добавку, содержащую соединение по любому из пп. 26-40; иa nutritional supplement containing a compound according to any one of paragraphs. 26-40; and один или более компонентов кетогенной диеты.one or more components of a ketogenic diet. 49. Композиция по п. 48, отличающаяся тем, что содержание указанного соединения в композиции составляет от примерно 1% масс./масс. до примерно 25% масс./масс., или от примерно 5% масс./масс. до примерно 15% масс./масс., или примерно 10% масс./масс.49. The composition of claim 48, wherein the content of said compound in the composition is from about 1% w / w. up to about 25% wt./mass., or from about 5% wt./mass. up to about 15% wt./mass., or about 10% wt./mass. 50. Композиция по п. 48, где указанная кетогенная диета включает массовое отношение жира к белку и углеводам, составляющее от примерно 2:1 до примерно 10:1, или от примерно 3:1 до примерно 6:1, или примерно 4:1.50. The composition according to p. 48, where the specified ketogenic diet includes a mass ratio of fat to protein and carbohydrates, comprising from about 2: 1 to about 10: 1, or from about 3: 1 to about 6: 1, or about 4: 1 .
RU2018143895A 2016-06-07 2017-06-02 Esters of beta-hydroxybutyrate and butanediol formed by medium-chain fatty acids and compositions and methods based on them RU2761829C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346975P 2016-06-07 2016-06-07
US62/346,975 2016-06-07
PCT/US2017/035826 WO2017213999A1 (en) 2016-06-07 2017-06-02 Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

Publications (3)

Publication Number Publication Date
RU2018143895A true RU2018143895A (en) 2020-07-09
RU2018143895A3 RU2018143895A3 (en) 2021-03-11
RU2761829C2 RU2761829C2 (en) 2021-12-13

Family

ID=60578899

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018143895A RU2761829C2 (en) 2016-06-07 2017-06-02 Esters of beta-hydroxybutyrate and butanediol formed by medium-chain fatty acids and compositions and methods based on them

Country Status (13)

Country Link
US (4) US10889538B2 (en)
EP (1) EP3465335A4 (en)
JP (3) JP7058610B2 (en)
KR (2) KR102638807B1 (en)
CN (2) CN109477993B (en)
AU (2) AU2017278099B2 (en)
CA (1) CA3026621A1 (en)
CO (1) CO2018014167A2 (en)
IL (2) IL263561B (en)
MX (2) MX2021009806A (en)
RU (1) RU2761829C2 (en)
SG (1) SG11201810765PA (en)
WO (1) WO2017213999A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017278099B2 (en) 2016-06-07 2021-03-11 Ithaca College Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
CN111050764A (en) 2017-07-21 2020-04-21 巴克老年研究所 β -hydroxybutyrate and butanediol S enantiomers and methods of use thereof
WO2019161047A1 (en) * 2018-02-14 2019-08-22 Bickman Benjamin Oral supplements of fatty acid and amino acid ketone esters to improve metabolic, physical and cognitive health
JP7391096B2 (en) * 2019-01-17 2023-12-04 ケトリピックス セラポーティクス ゲーエムベーハー Method for producing polyol-based esters of optionally acylated hydroxycarboxylic acids
WO2020147981A1 (en) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Process for preparing capped 3-hydroxycarboxylic acids and their salts and esters
BR112021014015A2 (en) * 2019-01-17 2021-09-21 Ioi Oleo Gmbh METHOD FOR THE PRODUCTION OF FATTY ALCOHOL ESTERS OF HYDROXYCARBOXYLIC ACIDS
CN110372502A (en) * 2019-07-25 2019-10-25 润泰化学（泰兴）有限公司 A kind of double esterification synthetic method of 1,3- glycol
GB201918657D0 (en) 2019-12-17 2020-01-29 Tdeltas Ltd Compounds for new use
CN116917264A (en) * 2020-07-13 2023-10-20 凯托利皮克斯治疗有限责任公司 Process for preparing hydroxybutyric acid carboxylic ester
CN112341542B (en) * 2021-01-08 2021-05-14 清华大学 3-hydroxybutyrylated modified protein medicine and preparation method and application thereof
WO2022164755A1 (en) * 2021-01-26 2022-08-04 Buck Institute For Research On Aging Use of exogenous ketone esters to induce weight loss in mammals

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263216A (en) 1978-10-20 1981-04-21 The Procter & Gamble Company Diglyceride manufacture
IL59407A (en) * 1979-03-06 1983-12-30 Sanofi Sa Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them
US4436726A (en) * 1980-12-15 1984-03-13 Fujisawa Pharmaceutical Co., Ltd. N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions
BE1001209A3 (en) 1987-11-19 1989-08-22 Solvay PHARMACEUTICAL CONTAINING ACID DERIVATIVE 3-hydroxybutanoic CHOSEN AMONG OLIGOMERS OF THIS ACID AND ESTERS OF THIS ACID OR WITH THESE OLIGOMERS 1.3-BUTANEDIOL.
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
EP0556387B1 (en) 1988-04-27 1995-08-09 Daicel Chemical Industries, Ltd. Process for preparing optically active 1,3-butanediol
JP2578658B2 (en) 1989-02-21 1997-02-05 チッソ株式会社 Optically active compound and method for producing the same
US5008126A (en) 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
IT1240760B (en) * 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti ACYL-L-CARNITINE ESTERS WITH GAMMA-HYDROXYBUTIRRIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM FOR THE INHIBITION OF NEURONAL DEGENERATION AND IN THE TREATMENT OF COMA.
EP0550779B1 (en) 1992-01-08 1995-10-18 Societe Des Produits Nestle S.A. Cosmetic and dermatologic composition containing diol diesters
DE19703471A1 (en) * 1997-01-31 1998-08-06 Beiersdorf Ag Cosmetic and dermatological sunscreen formulations containing triazine derivatives and butylene glycol diesters
ZA982253B (en) * 1997-03-17 1999-09-17 British Tech Group Therapeutic compositions.
DE69841002D1 (en) * 1997-05-14 2009-09-03 Univ British Columbia Highly effective encapsulation of nucleic acids in lipid vesicles
EP1052240B1 (en) * 1999-05-11 2003-03-19 Dow AgroSciences LLC Process for the preparation of substituted 3-hydroxybutyrate esters
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6703422B2 (en) * 2000-10-11 2004-03-09 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
EP1528053A1 (en) 2003-10-31 2005-05-04 Lonza Ag Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates
JP2006063001A (en) 2004-08-25 2006-03-09 Takasago Internatl Corp METHOD FOR PRODUCING OPTICALLY ACTIVE beta-BUTYROLACTONE
WO2007095262A2 (en) 2006-02-10 2007-08-23 Dupont Tate & Lyle Bio Products Company, Llc Bio-derived 1,3-propanediol and its conjugate esters as natural and non irritating solvents
JP5054418B2 (en) * 2007-04-23 2012-10-24 ポーラ化成工業株式会社 Skin external preparation suitable for cosmetics for cleansing
EP3296284B1 (en) 2008-08-21 2021-12-01 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Non-therapeutical use of hydroxybutyrate ester
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
WO2010120300A1 (en) 2009-04-16 2010-10-21 Isis Innovation Limited Process for the preparation of (3r)-hydr0xybutyl (3r) -hydroxybutyrate by enzymatic enantioselective reduction employing lactobacillus brevis alcohol dehydrogenase
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CA2797679A1 (en) 2010-04-28 2011-11-03 Arkema Inc. Method of improving stability of polyurethane polyol blends containing halogenated olefin blowing agent
KR101243240B1 (en) * 2010-07-19 2013-04-04 (주)에이씨티 Novel derivatives of alkyldiol compound and whitening composition for external skin comprising the same
CN103360243B (en) * 2012-03-31 2015-06-17 中国石油化工股份有限公司 Preparation method of 1,3-diacyloxy dimethylmethane compound
JP5146628B1 (en) 2012-05-01 2013-02-20 コニカミノルタアドバンストレイヤー株式会社 Retardation film, method of manufacturing polarizing plate, and liquid crystal display device
DK2984066T3 (en) 2013-03-14 2017-05-08 Univ Oxford Innovation Ltd Process for preparing (R) -hydroxybutyl (R) -3-hydroxybutyrate
SG11201506780RA (en) 2013-03-19 2015-10-29 Univ South Florida Compositions and methods for producing elevated and sustained ketosis
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
KR102255778B1 (en) * 2013-08-06 2021-05-24 이마고 바이오사이언시즈 인코포레이티드 Kdm1a inhibitors for the treatment of disease
US20180008629A1 (en) 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
AU2017278099B2 (en) 2016-06-07 2021-03-11 Ithaca College Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
CN111050764A (en) 2017-07-21 2020-04-21 巴克老年研究所 β -hydroxybutyrate and butanediol S enantiomers and methods of use thereof
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20190262415A1 (en) 2018-02-26 2019-08-29 Ketologie LLC Supplement for inducing and sustaining nutritional ketosis

Also Published As

Publication number Publication date
KR102638807B1 (en) 2024-02-21
MX2018015302A (en) 2019-08-22
EP3465335A4 (en) 2020-03-11
RU2018143895A3 (en) 2021-03-11
CA3026621A1 (en) 2017-12-14
AU2021203726B2 (en) 2023-04-06
JP2019525899A (en) 2019-09-12
IL263561B (en) 2022-04-01
US10647658B2 (en) 2020-05-12
AU2021203726A1 (en) 2021-07-01
JP2022020701A (en) 2022-02-01
US10562839B2 (en) 2020-02-18
CN109477993A (en) 2019-03-15
CN109477993B (en) 2023-03-28
US20190248730A1 (en) 2019-08-15
BR112018075102A8 (en) 2023-04-11
IL291694A (en) 2022-05-01
US20210171432A1 (en) 2021-06-10
AU2017278099A1 (en) 2018-12-20
SG11201810765PA (en) 2018-12-28
WO2017213999A1 (en) 2017-12-14
KR20190026747A (en) 2019-03-13
KR102519244B1 (en) 2023-04-06
CO2018014167A2 (en) 2019-01-18
JP7479337B2 (en) 2024-05-08
KR20230006926A (en) 2023-01-11
AU2021203726C1 (en) 2023-10-12
EP3465335A1 (en) 2019-04-10
MX2021009806A (en) 2022-11-30
BR112018075102A2 (en) 2019-03-26
US20190382333A1 (en) 2019-12-19
AU2017278099B2 (en) 2021-03-11
JP7058610B2 (en) 2022-04-22
JP2024028287A (en) 2024-03-04
US20190359551A1 (en) 2019-11-28
CN114292190A (en) 2022-04-08
RU2761829C2 (en) 2021-12-13
US10889538B2 (en) 2021-01-12
US11608308B2 (en) 2023-03-21
IL263561A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
RU2018143895A (en) FORMATED BY MEDIUM-RADIATED FATTY ACIDS, COMPLEXES OF BETA HYDROXIBUTIRATE AND BUTANDIOL, AND COMPOSITIONS AND METHODS ON THEIR BASIS
JP2019525899A5 (en)
RU2012122059A (en) CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS
CA2482004A1 (en) Compounds having unique cb1 receptor binding selectivity and methods for their production and use
JP2006516987A5 (en)
RU2018108136A (en) COMPOSITIONS CONTAINING UROLITINS
JP2018538273A5 (en)
CA2796744A1 (en) Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP2017508794A5 (en)
JP2018533618A5 (en)
JP2014505702A5 (en)
CA2936707C (en) Diaminoguanidine derivatives and application thereof in preparation of animal growth promoters used in feed
JP2019523279A5 (en)
CA2954548A1 (en) Enrichment of palmitoleic acid and palmitoleic acid derivatives by dry and solvent-aided winterization
NZ729455A (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
MX2022006990A (en) Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative.
RU2019102757A (en) ETHYNYL DERIVATIVES
FR3050639B1 (en) NEW FOOD AND MEDICINE SUPPLEMENT
JP2020515520A5 (en)
RU2019105352A (en) Long-acting DPP-IV inhibitor crystal and its salt
US10898460B1 (en) Leishmania inhibitors
RU2016115374A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBACTERIAL AGENTS
RU2017135950A (en) Compositions for treating fibrosis and fibrosis related conditions
JP2017109944A5 (en)
Sterol et al. Inhibition of Growth of G3H Mice by Ethionine and its Alleviation by Methionine or Choline.